{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:24:37Z","timestamp":1749756277891,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T00:00:00Z","timestamp":1566259200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T00:00:00Z","timestamp":1566259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12969-019-0361-2","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T13:00:48Z","timestamp":1566306048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Biologics in refractory myositis: experience in juvenile vs. adult myositis; part II: emerging biologic and other therapies on the horizon"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-1011","authenticated-orcid":false,"given":"Anjali","family":"Patwardhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles H.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,20]]},"reference":[{"issue":"4","key":"361_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.nmd.2005.12.008","volume":"16","author":"MC Dalakas","year":"2006","unstructured":"Dalakas MC. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul Disord. 2006;16(4):223\u201336.","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"361_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrrheum.2011.39","volume":"7","author":"M Zong","year":"2011","unstructured":"Zong M, Lundberg IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol. 2011;7(5):297\u2013306.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"361_CR3","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.bbadis.2014.05.034","volume":"1852","author":"YB Luo","year":"2015","unstructured":"Luo YB, Mastaglia FL. Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophys Acta. 2015;1852(4):622\u201332.","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"361_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.nmd.2014.06.432","volume":"24","author":"EM Moran","year":"2014","unstructured":"Moran EM, Mastaglia FL. The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications. Neuromuscul Disord. 2014;24(11):943\u201352.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"361_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s11926-012-0242-x","volume":"14","author":"A Tournadre","year":"2012","unstructured":"Tournadre A, Miossec P. Interleukin-17 in inflammatory myopathies. Curr Rheumatol Rep. 2012;14(3):252\u20136.","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"361_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/cei.12445","volume":"178","author":"EM Moran","year":"2014","unstructured":"Moran EM, Mastaglia FL. Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol. 2014;178(3):405\u201315.","journal-title":"Clin Exp Immunol"},{"issue":"24","key":"361_CR7","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","volume":"83","author":"AA Amato","year":"2014","unstructured":"Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014;83(24):2239\u201346.","journal-title":"Neurology"},{"issue":"3","key":"361_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/00207454.2018.1527329","volume":"129","author":"Mavroudis Ioannis","year":"2018","unstructured":"Ioannis M, Foivos P, Dimitrios K. A review on the treatment of sporadic inclusion body myositis with Bimagrumab and Alemtuzumab. Int J Neurosci. 2019;129(3):297\u2013302.","journal-title":"International Journal of Neuroscience"},{"issue":"2","key":"361_CR9","first-page":"450","volume":"63","author":"DA Isenberg","year":"1986","unstructured":"Isenberg DA, Rowe D, Shearer M, Novick D, Beverley PC. Localization of interferons and interleukin 2 in polymyositis and muscular dystrophy. Clin Exp Immunol. 1986;63(2):450\u20138.","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"361_CR10","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1002\/art.24936","volume":"60","author":"H Bilgic","year":"2009","unstructured":"Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 2009;60(11):3436\u201346.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"361_CR11","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/ard.2010.139949","volume":"70","author":"AP Liao","year":"2011","unstructured":"Liao AP, Salajegheh M, Nazareno R, Kagan JC, Jubin RG, Greenberg SA. Interferon beta is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis. 2011;70(5):831\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"361_CR12","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1365-2230.2006.02150.x","volume":"31","author":"J Wenzel","year":"2006","unstructured":"Wenzel J, Schmidt R, Proelss J, Zahn S, Bieber T, Tuting T. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol. 2006;31(4):576\u201382.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"361_CR13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ana.20464","volume":"57","author":"SA Greenberg","year":"2005","unstructured":"Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57(5):664\u201378.","journal-title":"Ann Neurol"},{"issue":"6","key":"361_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/ar3531","volume":"13","author":"EC Baechler","year":"2011","unstructured":"Baechler EC, Bilgic H, Reed AM. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther. 2011;13(6):249.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"361_CR15","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/BOR.0000000000000109","volume":"26","author":"IE Lundberg","year":"2014","unstructured":"Lundberg IE, Vencovsky J, Alexanderson H. Therapy of myositis: biological and physical. Curr Opin Rheumatol. 2014;26(6):704\u201311.","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"361_CR16","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1002\/art.34659","volume":"64","author":"AM Reed","year":"2012","unstructured":"Reed AM, Peterson E, Bilgic H, Ytterberg SR, Amin S, Hein MS, et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum. 2012;64(12):4078\u201386.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"361_CR17","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/art.24555","volume":"60","author":"TB Niewold","year":"2009","unstructured":"Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum. 2009;60(6):1815\u201324.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"361_CR18","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/bjd.15006","volume":"176","author":"C Huard","year":"2017","unstructured":"Huard C, Gulla SV, Bennett DV, Coyle AJ, Vleugels RA, Greenberg SA. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon beta in dermatomyositis. Br J Dermatol. 2017;176(5):1224\u201330.","journal-title":"Br J Dermatol"},{"issue":"11","key":"361_CR19","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1136\/ard.2011.150326","volume":"70","author":"BW Higgs","year":"2011","unstructured":"Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011;70(11):2029\u201336.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"361_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/gene.2011.61","volume":"13","author":"SA Greenberg","year":"2012","unstructured":"Greenberg SA, Higgs BW, Morehouse C, Walsh RJ, Kong SW, Brohawn P, et al. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun. 2012;13(3):207\u201313.","journal-title":"Genes Immun"},{"issue":"11","key":"361_CR21","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1002\/art.22928","volume":"56","author":"RJ Walsh","year":"2007","unstructured":"Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007;56(11):3784\u201392.","journal-title":"Arthritis Rheum"},{"issue":"1\u20132","key":"361_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","volume":"13","author":"EC Baechler","year":"2007","unstructured":"Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13(1\u20132):59\u201368.","journal-title":"Mol Med"},{"issue":"1","key":"361_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","volume":"73","author":"BW Higgs","year":"2014","unstructured":"Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, Guo X, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis. 2014;73(1):256\u201362.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"361_CR24","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/rheumatology\/ket413","volume":"53","author":"X Guo","year":"2014","unstructured":"Guo X, Higgs BW, Rebelatto M, Zhu W, Greth W, Yao Y, et al. Suppression of soluble T cell-associated proteins by an anti-interferon-alpha monoclonal antibody in adult patients with dermatomyositis or polymyositis. Rheumatology (Oxford). 2014;53(4):686\u201395.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"361_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijwd.2017.05.001","volume":"3","author":"CO Anyanwu","year":"2017","unstructured":"Anyanwu CO, Chansky PB, Feng R, Carr K, Okawa J, Werth VP. The systemic management of cutaneous dermatomyositis: results of a stepwise strategy. Int J Womens Dermatol. 2017;3(4):189\u201394.","journal-title":"Int J Womens Dermatol"},{"issue":"16","key":"361_CR26","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, et al. Apremilast for Behcet\u2019s syndrome--a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510\u20138.","journal-title":"N Engl J Med"},{"key":"361_CR27","unstructured":"ClinicalTrials.gov. A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01140503 ."},{"issue":"2","key":"361_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jdcr.2018.11.019","volume":"5","author":"C Bitar","year":"2019","unstructured":"Bitar C, Maghfour J, Ho-Pham H, Stumpf B, Boh E. Apremilast as a potential treatment for moderate to severe dermatomyositis: a retrospective study of 3 patients. JAAD Case Rep. 2019;5(2):191\u20134.","journal-title":"JAAD Case Rep"},{"key":"361_CR29","volume-title":"Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis","author":"ClinicalTrials.gov","year":"2018","unstructured":"ClinicalTrials.gov. Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis. 2018 Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03529955 ."},{"issue":"7","key":"361_CR30","first-page":"1017","volume":"3","author":"M Kaplan","year":"2002","unstructured":"Kaplan M. Eculizumab (Alexion). Curr Opin Investig Drugs. 2002;3(7):1017\u201323.","journal-title":"Curr Opin Investig Drugs"},{"key":"361_CR31","first-page":"S489","volume-title":"A pilot study of eculizumab in patients with dermatomyositis","author":"K Takada","year":"2002","unstructured":"Takada K, Bookbinder S, Furie R. A pilot study of eculizumab in patients with dermatomyositis; 2002. p. S489."},{"key":"361_CR32","doi-asserted-by":"publisher","first-page":"S489","DOI":"10.1002\/art.10125","volume":"46","author":"T Kazuki","year":"2002","unstructured":"Kazuki T, Bookbinder S, Furie R. A pilot study of eculizumab in patients with dermatomyositis. Arthritis Res. 2002;46:S489.","journal-title":"Arthritis Res"},{"issue":"12","key":"361_CR33","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3899\/jrheum.180060","volume":"45","author":"STANISLAS FAGUER","year":"2018","unstructured":"Faguer S, Belliere J, Ribes D. Complement C5-blocking agent in refractory Dermatomyositis. J Rheumatol. 2018;45(12):1710-11.","journal-title":"The Journal of Rheumatology"},{"key":"361_CR34","volume-title":"Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis","author":"ClinicalTrials.Gov","year":"2000","unstructured":"ClinicalTrials.Gov. Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis 2000. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00005571 ."},{"issue":"8","key":"361_CR35","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1136\/annrheumdis-2014-205278","volume":"73","author":"J Zou","year":"2014","unstructured":"Zou J, Li T, Huang X, Chen S, Guo Q, Bao C. Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis. 2014;73(8):1591\u20133.","journal-title":"Ann Rheum Dis"},{"key":"361_CR36","volume-title":"Basiliximab Treating Interstitial Pneumonia of CADM","author":"ClinicalTrials.Gov","year":"2017","unstructured":"ClinicalTrials.Gov. Basiliximab Treating Interstitial Pneumonia of CADM 2017 Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03192657?term=NCT03192657&rank=1 ."},{"key":"361_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1196\/annals.1423.030","volume":"1110","author":"SD Lytton","year":"2007","unstructured":"Lytton SD, Denton CP, Nutzenberger AM. Treatment of autoimmune disease with rabbit anti-T lymphocyte globulin: clinical efficacy and potential mechanisms of action. Ann N Y Acad Sci. 2007;1110:285\u201396.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"361_CR38","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1212\/01.WNL.0000071852.27182.C7","volume":"61","author":"C Lindberg","year":"2003","unstructured":"Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology. 2003;61(2):260\u20132.","journal-title":"Neurology"},{"issue":"5","key":"361_CR39","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11926-996-0007-5","volume":"3","author":"LM Pachman","year":"2001","unstructured":"Pachman LM, Fedczyna TO, Lechman TS, Lutz J. Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity. Curr Rheumatol Rep. 2001;3(5):379\u201386.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"361_CR40","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1189\/jlb.69.1.98","volume":"69","author":"SJ Getting","year":"2001","unstructured":"Getting SJ, Allcock GH, Flower R, Perretti M. Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties. J Leukoc Biol. 2001;69(1):98\u2013104.","journal-title":"J Leukoc Biol"},{"key":"361_CR41","unstructured":"Mallinckrodt. H.P. Acthar (R) Gel: Mallinckrodt; 2016 [Available from: http:\/\/www.acthar.com\/pdf\/Acthar-PI.pdf ]accessed."},{"key":"361_CR42","first-page":"9068061","volume":"2016","author":"A Patel","year":"2016","unstructured":"Patel A, Seely G, Aggarwal R. Repository Corticotropin injection for treatment of idiopathic inflammatory myopathies. Case Rep Rheumatol. 2016;2016:9068061.","journal-title":"Case Rep Rheumatol"},{"key":"361_CR43","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/DDDT.S33110","volume":"6","author":"T Levine","year":"2012","unstructured":"Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther. 2012;6:133\u20139.","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"361_CR44","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/annrheumdis-2017-212047","volume":"77","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Marder G, Koontz DC, Nandkumar P, Qi Z, Oddis CV. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann Rheum Dis. 2018;77(5):720\u20137.","journal-title":"Ann Rheum Dis"},{"key":"361_CR45","first-page":"292","volume":"4","author":"TMM Levine","year":"2016","unstructured":"Levine TMM, Efthimiou P, Tandan R, Dikranian A, et al. H.P. Acthar\u00ae Gel in Dermatomyositis and Polymyositis Treatment Registry: an Interim Analysis. J Neurol Disord. 2016;4:292.","journal-title":"J Neurol Disord"},{"key":"361_CR46","doi-asserted-by":"crossref","unstructured":"Levine T, Saperstein D, Hank N, Katz J, Pestronk A, Oddis C, et al. ADAPT: Acthar in Dermatomyositis and Polymyositis Treatment Registry (P07.041). Neurology. 2013;80(7 Supplement):P07.041.","DOI":"10.1212\/WNL.80.7_supplement.P07.041"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0361-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-019-0361-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-019-0361-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T06:56:33Z","timestamp":1721631393000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-019-0361-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,20]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1186\/s12969-019-0361-2","relation":{},"ISSN":["1546-0096"],"issn-type":[{"type":"electronic","value":"1546-0096"}],"subject":[],"published":{"date-parts":[[2019,8,20]]},"assertion":[{"value":"25 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}